March 28th 2025
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Skills to Enhance the Patient-Provider Relationship in Complex Care Settings
February 12th 2025Gladys Antelo-Allen, associate director of education and training at Camden Coalition, dives into the foundational skills in complex care that can enhance provider education and facilitate trusting patient-provider relationships.
Watch
Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS
February 7th 2025Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Watch
Bridging Gaps in Complex Care: Gladys Antelo-Allen
February 7th 2025Gladys Antelo-Allen, associate director of Education and Training, Camden Coalition, dives into the essential skills of providing complex care: motivational interviewing, harm reduction, care planning, trauma-informed care, and de-escalation.
Watch
Personalized CLL Therapy With MRD Guidance Improves Survival Outcomes
February 6th 2025A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.
Read More
Balancing Risks and Opportunities of Utilizing AI in Health Data: Carrie Kozlowski
February 5th 2025In this interview, chief operating officer and cofounder of Upfront Healthcare, Carrie Kozlowski, OT, MBA, discusses the integration of artificial intelligence (AI) in health care, emphasizing both opportunities and risks.
Watch